|
WO2020232303A1
|
|
EpCAM BINDING PROTEINS AND METHODS OF USE
|
|
US2020270362A1
|
|
Msln targeting trispecific proteins and methods of use
|
|
US2020231672A1
|
|
Single chain variable fragment cd3 binding proteins
|
|
CA3114038A1
|
|
Dll3 binding proteins and methods of use
|
|
WO2020061526A1
|
|
Conditionally activated target-binding molecules
|
|
WO2020061482A1
|
|
Egfr binding proteins and methods of use
|
|
WO2020060593A1
|
|
Conditionally active receptors
|
|
WO2019222282A1
|
|
Conditionally activated binding protein comprising a sterically occluded target binding domain
|
|
WO2019222278A1
|
|
Dual binding moiety
|
|
EP3794038A1
|
|
Binding moiety for conditional activation of immunoglobulin molecules
|
|
US2019135930A1
|
|
B cell maturation antigen binding proteins
|
|
EP3694529A1
|
|
Trispecific proteins and methods of use
|
|
CA3063362A1
|
|
Msln targeting trispecific proteins and methods of use
|
|
KR20200026809A
|
|
Mesothelin binding protein
|
|
WO2018204717A1
|
|
Compositions and methods for adoptive cell therapies
|
|
US2020148771A1
|
|
Inducible monovalent antigen binding protein
|
|
WO2018160671A1
|
|
Targeted checkpoint inhibitors and methods of use
|
|
WO2018136725A1
|
|
Innate immune cell inducible binding proteins and methods of use
|
|
KR20190085542A
|
|
Prostate-specific antigen binding protein
|
|
CA3044729A1
|
|
Psma targeting trispecific proteins and methods of use
|
